DSM-Firmenich Ltd
DSFIR
ISIN CH1216478797 / Valor 121647879
DSM-Firmenich Ltd
UMushroom community rating:
About company
DSM-Firmenich Ltd is a company that recently completed the sale and transfer of its equity interest in DSM Jiangshan Pharmaceutical Co., Ltd. to Jingjiang Cosfocus Health Technology Co., Ltd. Additionally, the company has announced plans to repurchase 1,500,000 ordinary shares to cover commitments under its share-based compensation plans starting April 8, 2024. This move reflects the company's strategic focus on optimizing its business operations and ensuring financial stability.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (24.10.2025):
DSM-Firmenich Ltd reported strong financial results for the first half of 2025, demonstrating robust organic sales and earnings growth. The company effectively executed its strategic plan, advanced key initiatives such as the €1 billion share buyback program, and made significant progress in portfolio optimization, positioning itself well for the continued uncertain macroenvironment.
Strong Organic Sales Growth
The company achieved a 7% organic sales growth in H1 2025, supported by favorable business conditions and solid performance across key segments, including Perfumery & Beauty and Taste, Texture & Health.
Enhanced Adjusted EBITDA
Adjusted EBITDA increased by 29% to €1.260 billion in H1 2025 compared to €976 million in H1 2024, driven by good organic growth and contributions from synergies and the vitamin transformation program.
Strategic Initiatives Progress
DSM-Firmenich successfully completed the sale of its Feed Enzymes business for €1.5 billion and advanced the exit process from Animal Nutrition & Health, aligning with its long-term strategic goals.
Share Buyback Program
The €1 billion share buyback program commenced in April 2025 has been accelerated, with approximately 40% executed by July 30, 2025, and completion now targeted for January 2026.
Updated FY 2025 Outlook
The company updated its full-year 2025 outlook, projecting an Adjusted EBITDA of around €2.4 billion, factoring in contributions from ongoing strategic programs and market conditions.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
21649 M
Market cap (USD)
1,021,082
Daily traded volume (Shares)
97.88 / 96.54
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
